NewAmsterdam Pharma Co N.V. (NAMS): Total Assets
$769.28M
As of 2025-12-31
$704.45M
As of 2026-06-30
+17.1%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $769.28M | -11.0% | 2026-02-18, Balance as of period end |
| 2024-12-31 | $864.62M | +149.1% | 2026-02-18, Balance as of period end |
| 2023-12-31 | $347.10M | -27.5% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $478.50M | n/a | 2024-02-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $29.92M | -16.5% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $42.21M | +31.1% |
Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗